NCT06111014Phase 3Terminated

Continuation Study for Latozinemab

Study sponsor: Alector Inc. · ALEC

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-09-01Actual
Enrollment · participants17Actual
Source updated2026-01-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 35 participants (planned). After: 17 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 30 Jul 2027. After: 1 Sep 2025.

Recruitment status changed

Before: Enrolling by invitation. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview